Global Shingles Vaccine Market Opportunity
Prevalence of shingles is increasing across the globe, fueled mainly by increasing geriatric population. However, high cost of vaccines is limiting vaccination in emerging economies, characterized by inadequate insurance coverage. The major concern among healthcare experts is reduction in postherpetic neuralgia from the shingles vaccine. Zostavax has been successful to a certain extent in reducing postherpetic neuralgia due to the effect of the vaccine on reducing risk of developing herpes zoster. Better outcomes of Shingrix would be a boon for highly lucrative global shingles vaccines market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients